Black Diamond Therapeutics announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer, CEO, effective immediately. Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company. Dr. Velleca joined the Board of Directors of Black Diamond in 2021 and became Chairman of the Board in 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDTX:
- Black Diamond Therapeutics Announces CEO Transition
- Black Diamond Therapeutics doses first patient in Phase 1 trial of BDTX-1535
- Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
- Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics expects cash to fund requirements into 1H25
